Quality Executive Partners (QxP) is a global premier consulting and training firm to the pharma, biotech, and life sciences industries. QxP’s team of deeply skilled experts provide innovative and pragmatic solutions which address development, commercialization and business needs simultaneously. Our success is defined by the transfer of knowledge to our clients, enabling them to develop and commercialize quality products sustainably. QxP’s Cell & Gene Therapies Practice combines real-world cell and gene life cycle and aseptic operations industry experts. QxP’s immersive workforce education and training platform, Virtuosi, features risk-free VR training sessions in aseptic, microbiology, and CGT manufacturing, and is available in five languages.

Blood Centers of America (BCA) is the nation’s largest blood supply network, providing over 50 percent of the U.S. blood supply.  This national organization is comprised of over 60 independent community blood centers with a deep local commitment to the communities and patients they serve.

The BCA network encompasses over 500 collection and testing sites across the United States.  In addition to meeting the transfusion needs of the communities they serve, BCA members provide human blood products (including leukopaks), custom collections, cell processing, testing, storage, distribution and other services to the therapeutic, diagnostic and cell therapy industries.  BCA members actively collect and provide critical raw materials for manufacturing of autologous and allogeneic cell-based therapies.  Collectively BCA’s members interact with nearly four million individual blood donors annually.

In response to the COVID-19 pandemic, BCA optimized the collection of convalescent plasma (CCP) donations throughout the network from those recovered from COVID-19.  The BCA network collected and distributed over 70% of CCP in the U.S.

OrganaBio is a contract technology development and manufacturing organization (CTDMO) that manufactures clinical (cGMP) grade cells for cancer immunotherapy and regenerative medicine drug developers. OrganaBio’s vision is to accelerate the development of these drugs by giving developers access to:

• Fresh and scalable tissue supplies
• Cell isolation, purification, expansion, cryopreservation, and characterization services
• Process development services
• Clinical-grade manufacturing services.

Whether you desire cellular starting material, clinical trial services, process and assay development, or  manufacturing across the cell therapy continuum, OrganaBio provides access to these critical resources essential for therapeutic development while adhering to high standards of quality assurance and regulatory compliance. At OrganaBio, we empower our customers’ people, process, and products on their journey to commercialization.

Not only is OrganaBio exhibiting at booth 337 and would welcome the opportunity to learn more about your programs and needs, but we are also providing exclusive invitations to our pre-conference reception and a tour of our cGMP manufacturing facility – located just 30 minutes from the convention center – on January 17 between 1-3pm.  Please contact our Director of Marketing, Shilpa Ramesh (Shilpa.ramesh@organabio.com) to request an invitation to the reception or to schedule a meeting with the OrganaBio team.

Avectas is a cell engineering company that has pioneered – SOLUPORE® – a cell engineering technology platform enabling the manufacture of next-generation cell therapy products.​ It is differentiated from the competition by the quality of modified cells including their viability, functionality and proliferation. The platform comprises a novel physicochemical transfection system, enabling complex gene editing in a GMP-aligned process.

Avectas is a private, international company with research facilities in Dublin, as well as an office in Cambridge MA, USA.  It has over 30 employees and is led by a team of highly experienced pharmaceutical executives, who are supported by a world-class Scientific Advisory Board of cancer cell therapy experts. The Company has raised over US$50m to date.

Matica Biotechnology is a CDMO providing fully integrated cell and gene therapy development and manufacturing services. With industry-leading expertise in GMP manufacturing of bulk and final drug product, cell line development, process development, and assay development, Matica Bio supports its clients with expertise and streamlined operations from bench to filing. Its state-of-art facility in Texas has redefined excellence in the CDMO domain through innovative technology such as single-use technologies and in-line process monitoring to deliver cell and gene therapies faster, safer and at the highest level of quality. 

Single Use Support is an end-to-end solution provider for fluid management in the biopharmaceutical industry. Our products cover application areas ranging from small scale clinical trials or cell & gene therapy manufacturing up to commercial bulk drug substance handling and vaccine production. The product range from Single Use Support includes single-use consumables like bioprocess containers, manifold tubing assemblies and protective shells for single-use bags but also scalable platform technologies for controlled freezing & thawing and fill-filtration of your liquid substances.

Emerson is the leading supplier of automation solutions to the Life Sciences Industry, with automation expertise and technologies to solve your greatest cGMP manufacturing challenges.  Accelerate time to market for new therapeutics and increasing efficiencies for CGT manufacturing techniques.  Our consultants can help create effective solutions to improve inventory management, eliminate variability, and deliver cost effective compliance with repeatable production.  Ask our experts how our trusted brands such as DeltaV, Syncade, Rosemount, ASCO and more can empower your single use production.  From design to implementation, and start-up to on-going optimization, rely on Emerson to stay competitive in a global economy. 

 Visit Website

CAI is passionate about helping development-stage companies get their product to market faster. Any misstep on the path to commercialization drains capital, impacts valuation, and delays time to revenue. Most importantly, delays can impact patient access to novel, life-saving therapies. 

 Our industry experts work with you to characterize your product and process, and to apply the principles of quality by design, quality risk management and industry best practices to help you reach each milestone on the path to commercialization in the most efficient manner.   

Our integrated project delivery model enables you to accelerate process validation, tech transfer, manufacturing scale-up, vendor selection, quality system implementation and regulatory affairs from early clinical trials through scale-up to commercial manufacturing.   

CAI has over 25 years of experience and is an employee-owned company. We have a reputation for exceeding customer expectations. CAI is the partner you need to meet a higher standard. 

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is an organization funded by the United States Department of Defense. ARMI’s mission is to make practical the scalable manufacturing of engineered tissues and tissue-related technologies, to benefit existing industries and grow new ones. ARMI brings together a consortium of over 170 partners from across industry, government, academia, and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues, and organs.